1. Home
  2. RSF vs XLO Comparison

RSF vs XLO Comparison

Compare RSF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RiverNorth Capital and Income Fund

RSF

RiverNorth Capital and Income Fund

HOLD

Current Price

$14.57

Market Cap

58.6M

Sector

Finance

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$9.20

Market Cap

56.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSF
XLO
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
56.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RSF
XLO
Price
$14.57
$9.20
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
9.7K
34.9K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
10.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$14.23
$0.46
52 Week High
$15.07
$9.89

Technical Indicators

Market Signals
Indicator
RSF
XLO
Relative Strength Index (RSI) 54.10 56.63
Support Level $14.51 $7.47
Resistance Level $14.70 $9.89
Average True Range (ATR) 0.06 0.43
MACD 0.01 0.02
Stochastic Oscillator 78.81 67.94

Price Performance

Historical Comparison
RSF
XLO

About RSF RiverNorth Capital and Income Fund

RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: